Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic trial for predicting the effect site concentration of remimazolam at awakening
jRCTs031240098Active, not recruiting
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of remimazolam. Primary endpoint: Effect-site concentration of remimazolam at awakening. Started Jun 2025; status: active, not recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on jRCTs031240098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240098.